However, due to the relative infrequency of SAMS, its multicausal nature, and the costs and outcomes observed here, standalone SLCO1B1 testing may only be appropriate as a single test for patients predisposed to SAMS due to other risk factors or in a reactive manner for those who respond poorly to statin initiation [81,82]. This evidence concerns the gene SLCO1B1 and short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome.